Sponsor: Novartis
Protocol Number: CAIN457C2231
|
The purpose of this study is to demonstrate the efficacy and safety of secukinumab 300 milligram (mg) and 150 mg administered subcutaneously (s.c.) for 52 weeks in combination with prednisone tapered over 24 weeks in adult participants with PMR who have recently relapsed. |
Detailed Information: Here
To learn more or see if you qualify: Click Here